CDK-话题@MedSci

#CDK#

85篇内容 | 2843人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1435547, encodeId=dfbc143554ed0, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Acta Neuropathologica：伴有RELA改变的幕上膜室间隔瘤中CDKN2A缺失是提后不良的标志物：HIT室间隔瘤试验的回顾性分析, objectType=article, longId=199859, objectId=0de119985937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0de119985937, replyNumber=0, likeNumber=72, createdTime=2020-08-24, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0de119985937, moduleTitle=Acta Neuropathologica：伴有RELA改变的幕上膜室间隔瘤中CDKN2A缺失是提后不良的标志物：HIT室间隔瘤试验的回顾性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0de119985937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435546, encodeId=15e31435546b3, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Acta Neuropathologica：幕上室管膜瘤CDKN2A缺失伴RELA改变提示预后不佳:对HIT室管膜瘤试验队列的回顾性分析, objectType=article, longId=199078, objectId=33271990e893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33271990e893, replyNumber=0, likeNumber=44, createdTime=2020-08-11, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33271990e893, moduleTitle=Acta Neuropathologica：幕上室管膜瘤CDKN2A缺失伴RELA改变提示预后不佳:对HIT室管膜瘤试验队列的回顾性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33271990e893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435545, encodeId=504e143554556, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Acta Neuropathologica：CDKN2A / B纯合子缺失与脑膜瘤的早期复发有关, objectType=article, longId=197840, objectId=e1cf19e8401c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1cf19e8401c, replyNumber=0, likeNumber=80, createdTime=2020-07-22, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1cf19e8401c, moduleTitle=Acta Neuropathologica：CDKN2A / B纯合子缺失与脑膜瘤的早期复发有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1cf19e8401c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435544, encodeId=857414355445e, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , objectType=article, longId=195525, objectId=b61e195525f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61e195525f3, replyNumber=0, likeNumber=90, createdTime=2020-06-11, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61e195525f3, moduleTitle=Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61e195525f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435543, encodeId=5b151435543a2, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点, objectType=article, longId=193458, objectId=f73b193458ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f73b193458ee, replyNumber=0, likeNumber=72, createdTime=2020-05-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f73b193458ee, moduleTitle=Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f73b193458ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435542, encodeId=acb714355424f, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, objectType=article, longId=192539, objectId=63c019253993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63c019253993, replyNumber=0, likeNumber=77, createdTime=2020-04-21, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63c019253993, moduleTitle=Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63c019253993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435541, encodeId=b3df143554189, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长, objectType=article, longId=187870, objectId=4a7018e87076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a7018e87076, replyNumber=0, likeNumber=68, createdTime=2020-02-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a7018e87076, moduleTitle=Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a7018e87076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435540, encodeId=4ae4143554006, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, objectType=article, longId=186505, objectId=22ce186505e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ce186505e0, replyNumber=0, likeNumber=75, createdTime=2020-01-20, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ce186505e0, moduleTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22ce186505e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435539, encodeId=48db143553966, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cell Death Dis：SKA3通过调节CDK2/P53磷酸化促进肝癌发生发展, objectType=article, longId=185569, objectId=1c0718556936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c0718556936, replyNumber=0, likeNumber=63, createdTime=2020-01-03, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c0718556936, moduleTitle=Cell Death Dis：SKA3通过调节CDK2/P53磷酸化促进肝癌发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c0718556936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435538, encodeId=4d551435538e3, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者能量和蛋白质需求, objectType=article, longId=185226, objectId=015c185226dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015c185226dc, replyNumber=0, likeNumber=76, createdTime=2019-12-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015c185226dc, moduleTitle=2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者能量和蛋白质需求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015c185226dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435537, encodeId=cfcb143553ea7, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, objectType=article, longId=184839, objectId=a8c018483912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c018483912, replyNumber=0, likeNumber=119, createdTime=2019-12-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c018483912, moduleTitle=诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c018483912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435536, encodeId=151c1435536cb, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待, objectType=article, longId=184341, objectId=14291843415e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14291843415e, replyNumber=0, likeNumber=82, createdTime=2019-12-08, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14291843415e, moduleTitle=CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14291843415e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435535, encodeId=2348143553523, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, objectType=article, longId=184135, objectId=48f018413537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f018413537, replyNumber=0, likeNumber=0, createdTime=2019-12-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f018413537, moduleTitle=CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48f018413537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435534, encodeId=0d2b143553488, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者钙磷饮食管理, objectType=article, longId=183768, objectId=7137183e68bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7137183e68bc, replyNumber=0, likeNumber=72, createdTime=2019-11-30, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7137183e68bc, moduleTitle=2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者钙磷饮食管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7137183e68bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435533, encodeId=214a1435533f8, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, objectType=article, longId=180695, objectId=da1a180695a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da1a180695a6, replyNumber=0, likeNumber=82, createdTime=2019-10-10, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da1a180695a6, moduleTitle=氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da1a180695a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435532, encodeId=72b31435532ae, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, objectType=article, longId=180364, objectId=f1771803649f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1771803649f, replyNumber=0, likeNumber=70, createdTime=2019-10-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1771803649f, moduleTitle=2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1771803649f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435531, encodeId=3f451435531aa, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌, objectType=article, longId=180187, objectId=220318018e7e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=220318018e7e, replyNumber=0, likeNumber=83, createdTime=2019-09-28, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=220318018e7e, moduleTitle=Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=220318018e7e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435530, encodeId=fb9b143553065, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破, objectType=article, longId=180007, objectId=c6d618000e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6d618000e24, replyNumber=0, likeNumber=73, createdTime=2019-09-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6d618000e24, moduleTitle=EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6d618000e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435529, encodeId=6bac1435529e0, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性, objectType=article, longId=178015, objectId=77ed1e8015f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77ed1e8015f9, replyNumber=0, likeNumber=75, createdTime=2019-08-22, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77ed1e8015f9, moduleTitle=Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77ed1e8015f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1435528, encodeId=e1f41435528ac, content=<a href='/topic/show?id=09dc439915' target=_blank style='color:#2F92EE;'>#CDK#</a>, objectTitle=NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌, objectType=article, longId=176285, objectId=ac241e628571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac241e628571, replyNumber=0, likeNumber=75, createdTime=2019-07-28, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac241e628571, moduleTitle=NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac241e628571)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CDK

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Acta Neuropathologica：伴有RELA改变的幕上膜室间隔瘤中CDKN2A缺失是提后不良的标志物：HIT室间隔瘤试验的回顾性分析

2020-08-24

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Acta Neuropathologica：幕上室管膜瘤CDKN2A缺失伴RELA改变提示预后不佳:对HIT室管膜瘤试验队列的回顾性分析

2020-08-11

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Acta Neuropathologica：CDKN2A / B纯合子缺失与脑膜瘤的早期复发有关

2020-07-22

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Brit J Cancer：CDK4/6抑制剂可用于儿科和成人生殖细胞瘤治疗

2020-06-11

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点

2020-05-05

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cell Death Dis：CDK4/6抑制剂联合PARP抑制剂或可进一步提高乳腺癌的治疗效果

2020-04-21

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Blood：CDK6特异性PROTACs选择性抑制Ph+ALL细胞生长

2020-02-13

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌

2020-01-20

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cell Death Dis：SKA3通过调节CDK2/P53磷酸化促进肝癌发生发展

2020-01-03

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者能量和蛋白质需求

2019-12-26

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

诺华的CDK4/6抑制剂Kisquali治疗晚期或转移的乳腺癌临床试验成功

2019-12-18

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂前途，乳腺癌免疫疗法值得期待

2019-12-08

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

CDK4/6抑制剂哌柏西利给HR+晚期乳腺癌患者更长生存、更好生活

2019-12-05

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2019 儿童肾脏营养组建议：儿童2-5期CDK患者及透析患者钙磷饮食管理

2019-11-30

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

氟维司群联合CDK4/6i改写HR+/HER2+晚期乳腺癌治疗模式

2019-10-10

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

2019 ESMO：CDK4 / 6抑制作用可提高HR + / HER2-晚期乳腺癌患者的生存率

2019-10-02

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Cancer Discov：CDK7抑制剂能够通过MED1去激活抑制去势抵抗性前列腺癌

2019-09-28

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

EMBO Mol Med：化疗脱发？靶向药CDK4/6抑制剂或将带来防脱发新突破

2019-09-26

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

Sci transl med：MDM2拮抗剂可克服黑色素瘤对CDK4/6抑制剂的耐药性

2019-08-22

zhouqu_8 (审核中...)

前往app查看评论内容

#CDK#

NEJM：CDK4/6抑制剂联合内分泌疗法治疗晚期乳腺癌

2019-07-28

科室
- - 订阅+
  - 更多科室
工具
服务